Risk of hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients with myeloproliferative neoplasms treated with ruxolitinib.
Alejandro Garcia-HortonElliot SmithDawn MazeCaroline McNamaraHassan SibaiVikas GuptaPublished in: Leukemia & lymphoma (2020)
Keyphrases